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Abstract
Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a
number of solid and hematologic malignancies. Its clinical utility as an oral anticancer agent, however, is limited by poor oral
bioavailability and gastrointestinal toxicity. Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-
POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration. We
characterized the activity of CPX-POM and its major metabolites in in vitro and in vivo preclinical models of high-grade
urothelial cancer. CPX inhibited cell proliferation, clonogenicity and spheroid formation, and increased cell cycle arrest at S
and G0/G1 phases. Mechanistically, CPX suppressed activation of Notch signaling. Molecular modeling and cellular thermal
shift assays demonstrated CPX binding to γ-secretase complex proteins Presenilin 1 and Nicastrin, which are essential for
Notch activation. To establish in vivo preclinical proof of principle, we tested fosciclopirox in the validated N-butyl-N-(4-
hydroxybutyl) nitrosamine (BBN) mouse bladder cancer model. Once-daily intraperitoneal administration of CPX-POM for
four weeks at doses of 235mg/kg and 470mg/kg significantly decreased bladder weight, a surrogate for tumor volume,
and resulted in a migration to lower stage tumors in CPX-POM treated animals. This was coupled with a reduction in the
proliferation index. Additionally, there was a reduction in Presenilin 1 and Hes-1 expression in the bladder tissues of CPX-
POM treated animals. Following the completion of the first-in-human Phase 1 trial (NCT03348514), the pharmacologic
activity of fosciclopirox is currently being characterized in a Phase 1 expansion cohort study of muscle-invasive bladder
cancer patients scheduled for cystectomy (NCT04608045) as well as a Phase 2 trial of newly diagnosed and recurrent
urothelial cancer patients scheduled for transurethral resection of bladder tumors (NCT04525131).
Introduction
Bladder cancer is the 6th most common solid tumor in
the United States with an estimated 83,730 new cases and
17,200 deaths in 20211. There are an estimated 699,450
people living with this disease in the United States2. The
disease has a high risk of recurrence and progression that
requires life-long surveillance, making this the most
expensive cancer to treat on a per-patient-lifetime-basis3.
While the overall 5-year survival rate for bladder cancer is
77%, in those with advanced disease, this rate can be as
low as 4%4.
Bladder cancer is defined as two diseases, each with
different treatment approaches and outcomes. Most
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newly diagnosed patients have non-muscle-invasive
bladder cancer (NMIBC), which is generally considered
less life-threatening than muscle-invasive bladder cancer
(MIBC)5. However, in spite of endoscopic resection fol-
lowed by intravesical immunotherapy (Bacillus Calmette-
Guerin (BCG)) or chemotherapy (e.g., Mitomycin C,
Gemcitabine), 60–70% of those with NMIBC will recur
and 20–30% will progress to MIBC6, where the gold
standard treatment is radical cystectomy coupled with
cisplatin-based chemotherapy7. Additionally, patients who
progress from NMIBC to MIBC have worse survival than
those who present with de novo MIBC8.
Ciclopirox is a synthetic antifungal agent approved for
topical dermatologic use in the treatment of a broad
spectrum of fungal organisms9. The active pharmaceutical
ingredient is either the free acid (CPX) or olamine salt
(CPX-O). CPX is thought to act through the chelation of
polyvalent metal cations, such as Fe3+ and Al3+, resulting
in the inhibition of the metal-dependent enzyme systems
(e.g., cytochromes, catalase, and peroxidase), and disrup-
tion of mitochondrial electron transport processes and
energy production10. Preclinical studies have also shown
anticancer activity of CPX in numerous solid tumors and
hematologic cancers11–25. CPX decreased cell growth and
viability of primary acute myeloid leukemia (AML) cells11.
Moreover, CPX inhibited Wnt signaling21. Oral adminis-
tration of CPX-O in patients with relapsed or refractory
hematologic malignancies resulted in low circulating
plasma CPX concentrations and Grade 3 dose-limiting
gastrointestinal toxicities26. These observations led to the
conclusion that CPX lacks clinical utility as an oral
anticancer agent. Unfortunately, CPX and CPX-O also
lack solubility properties necessary to formulate the drug
as an injectable product.
In an effort to further evaluate CPX as an anticancer
agent, we synthesized a phosphoryloxymethyl ester of
CPX, fosciclopirox (Ciclopirox Prodrug, CPX-POM) (Fig.
1A). CPX-POM has outstanding water solubility and is
readily formulated for parenteral administration. We then
determined the activity of fosciclopirox in high-grade
urothelial cancer in in vitro and in vivo preclinical models.
We observed significant anticancer activity in several
human high-grade bladder cancer cell lines. In addition,
we observed activity in vivo employing a chemical carci-
nogen mouse model of bladder cancer. Mechanistically,
we show that CPX binds to γ-secretase proteins Presenilin
1 and Nicastrin and inhibits Notch activation.
Results
Test article for in vitro studies
Following intravenous administration, CPX-POM is
rapidly and completely metabolized to its active metabo-
lite, ciclopirox (CPX) via circulating phosphatases27. CPX-
POM is typically not detected in plasma nor urine in mice,
rats, and dogs27. Once formed, CPX is extensively meta-
bolized to form ciclopirox glucuronide (CPX-G) followed
by urinary excretion27. The active metabolite is also
excreted in urine, and as described herein, achieves
steady-state urinary concentrations that exceed in vitro
IC50 values by several fold at well-tolerated doses in mice.
In vitro studies in the T24 high-grade human urothelial
cancer cell line demonstrated that CPX-POM and CPX-G
have little (IC50 > 50 µM) to no anticancer activity. As a
result, in vitro studies described herein were conducted
using the active metabolite, CPX, as the test article.
CPX inhibits growth of bladder cancer cells
We first determined the effect of CPX on high-grade
human urothelial cancer cell lines including T24, UM-
UC-3, HTB-9, HTB-5, HT-1376, and RT-4 cells.
Treatment with CPX significantly suppressed the pro-
liferation of all six cell lines in a concentration- and
time-dependent manner (Fig. 1B, Supplementary Fig.
1a). We next determined the long-term effect of short-
term CPX exposure employing the clonogenicity assay.
Treatment with CPX significantly suppressed the
number of colonies in T24, UM-UC-3, HTB-9, HTB-5,
HT-1376, and RT-4 cells (Fig. 1C, D). Furthermore,
CPX exposure to an immortalized normal human uro-
thelial cell line (UROtsa) demonstrated cytotoxicity at
exposures exceeding 20 µM (Supplementary Fig. 1b),
compared to IC50 values of 1.5–10 µM in the six uro-
thelial cancer cell lines studied.
CPX induces cell cycle arrest and apoptosis
We next determined whether CPX mediated suppres-
sion of cell growth was due to effects on cell cycle pro-
gression. We treated T24 and UM-UC-3 cells with 4 µM
concentrations of CPX followed by flow cytometric, ana-
lyses. Treatment with CPX resulted in a significant
increase in cells in G0/G1 in T24 cells. In UM-UC-3 cells,
a significant increase in cells in the S-phase of the cell
cycle was observed. Together, these data suggest CPX
induces cell cycle arrest (Fig. 2A, B).
Cyclins play a significant role in cell cycle progression.
They bind to cyclin-dependent kinases and regulate dif-
ferent cell cycle transitions, and their deregulation can
lead to tumor progression28. Therefore, we next deter-
mined the effect of 4 µM CPX on the expression of cyclin
D1, B1, A2, and E in T24 and UM-UC-3 cells. Protein
levels of Cyclin D1 and B1 were significantly reduced
following CPX incubation at 4 µM in both T24 and UM-
UC-3 cells (Fig. 2C). Given cyclin D1 plays a significant
role in the progression from G1 to S-phase of the cell
cycle, we also confirmed by immunofluorescence its
expression was reduced significantly (Fig. 2D). Further, we
determined whether CPX induced apoptosis utilizing
Annexin V/PI staining and flow cytometry. We observed
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Fig. 1 CPX inhibits proliferation and colony formation in bladder cancer cells. A Chemical structures of CPX and CPX-POM. B CPX inhibits
proliferation of bladder cancer cell lines (T24, UM-UC-3, HTB-9, HTB-5, HT-1376, and RT-4). Cells were incubated with increasing concentration
(0–40 μM) of CPX for up to 72 h. The treatment showed a significant dose and time-dependent decrease in cell proliferation when compared with
untreated controls in the bladder cancer cell lines. C CPX inhibits colony formation. Cells were incubated with 0–20 μM CPX for 48 h and allowed to
grow into colonies for 10 d. Incubation with CPX inhibits clonogenicity and number of colonies in bladder cancer cell lines (D).
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Fig. 2 CPX induces cell cycle arrest in bladder cancer cell lines. A Cell cycle analysis of CPX-treated cells. T24 and UM-UC-3 cells were treated with
4 µM concentrations of CPX, and examined by flow cytometry. CPX treatment-induced G0/G1 arrest in T24 cells and S-phase arrest in UM-UC-3 cells.
The percent cells in each phase are presented graphically (B). C CPX downregulates cyclin D1 and B1 expression in T24 and UM-UC-3 cells as assessed
by western blot. D Immunofluroscence analysis shows downregulation of cyclin D1 expression after CPX treatment in T24 cells.
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that when T24 cells were treated with CPX, there was an
increase in the percentage of cells in the early and late
apoptotic stage compared to untreated cells. In CPX-
treated UM-UC-3 cells, an increase in the percentage of
cells in the late apoptotic stage was also detected com-
pared to untreated cells (Fig. 3A-C). There was a time-
dependent increase in the number of early and late
apoptotic cells over 72 h post-treatment. We confirmed
apoptosis by immunofluorescence for annexin V, a critical
protein that is expressed when cells are undergoing
apoptosis (Fig. 3D). Exposure to CPX reduced levels of the
antiapoptotic marker proteins Bcl-xL and Bcl-2 in both
T24 and UM-UC-3 cells (Fig. 3E). In addition, there were
increases in the levels of cleaved PARP protein in these
cell lines after CPX treatment (Fig. 3E). Cell death can
result from multiple pathways, including autophagy and
apoptosis. The key effector proteins for autophagy and
apoptosis are LC3B29 and activated caspase-330, respec-
tively. We observed that 24 h following incubation with
CPX at 4 µM, there was a significant increase in the
generation of LC3B protein levels in T24 and UM-UC-3
cells, while at 48 h, we observed increases in both LC3B
and cleaved caspase-3 (Fig. 3F). Taken together, these data
suggest that at early time points, CPX induces urothelial
cancer cells to undergo autophagy which subsequently
switches to apoptosis.
CPX inhibits bladder cancer spheroid growth and cell
migration
A critical aspect of tumor survival is the presence of
cancer stem cells (CSCs), which are believed to preserve
themselves and divide asymmetrically to generate pro-
genitors that can differentiate to form various cells in the
tumor31. We determined whether CPX can also affect
CSCs, by plating T24, UM-UC-3, HT-1376, HTB-9, and
RT-4 cells in ultralow binding plates under conditions
that favor the growth of spheroids. In the presence of
CPX, there was a dose-dependent reduction in the size
and number of primary spheroids (Fig. 4A, B). A critical
experiment to confirm that cancer stem cells are affected
is to take the primary spheroids exposed to CPX, and
plate them in secondary and tertiary spheroids with no
additional treatment. Replating of the primary spheroids
exposed to CPX demonstrated that no spheroids devel-
oped, suggesting that CPX reduced the viability of CSCs.
Furthermore, CPX treatment reduced the expression of
bladder cancer stem cell marker proteins SOX9 and CD44
(Fig. 4C).
To analyze whether CPX further affects cell migration,
we first performed the wound-healing assay, where
scratch streaks were made on 90–95% confluent T24 and
UM-UC-3 cells. After 24 h, closure of the cell-free areas
was significantly reduced in the presence of CPX (Fig. 4D,
E). These data indicated that CPX decreased the
migratory ability of the cells. Further, we performed the
Boyden chamber assay to characterize the effects of CPX
on migration. We treated T24 and UM-UC-3 cells with
CPX followed by measurement of cell migration over
12 h. CPX treatment significantly reduced the migration
of bladder cancer cell lines (Fig. 4F, G). We also deter-
mined whether CPX inhibits cell invasion. For this, we
plated T24 cells in Matrigel containing tissue culture
inserts and after 24 h, cell invasion into the matrigel was
determined. At the ½ IC50 of 2 µM, CPX significantly
suppressed the invasion of T24 cells through the matrigel
(Supplementary Fig. 2). These data suggest CPX sup-
presses bladder cancer migration and invasion, critical
factors in cancer cell metastasis.
CPX targets Notch signaling by inactivating γ-secretase
proteins
Several published studies report that CPX targets ribo-
nucleotide reductase to suppress cell transition from G1
to S-phase of the cell cycle11. Ribonucleotide reductase is
an iron-dependent enzyme that is essential for DNA
synthesis, and iron chelators such as deferoxamine inhibit
their activity in proliferating cells32,33. To determine
whether CPX inhibits urothelial cancer cell proliferation
by primarily chelating iron, we tested whether deferox-
amine also affects urothelial cancer growth. Deferoxamine
affected neither T24 cell proliferation nor spheroid for-
mation (Supplementary Fig. 3a, b). With the suggestion
that inhibition of urothelial cancer cell proliferation is
mediated by mechanism(s) other than, or in addition to
inhibition of ribonucleotide reductase, we performed a
qPCR-based array to examine the expression of proteins
from various pathways following CPX treatment. We
chose a stem cell-based array and observed inhibition in
the expression of genes at the mRNA level involved in the
Notch signaling pathway in T24 cells treated with 4 µM
CPX (Fig. 5A). The Notch pathway is reported to possess
tumor-promoting and tumor-suppressor roles in can-
cer34,35. It has been suggested that Notch signaling
represents an attractive target for the treatment of bladder
cancer. Notch is a transmembrane receptor that is acti-
vated by the serial cleavage activities of ADAM/TACE
and γ-secretase proteins. These cleavage events result in
the release of the intracellular domains (NICD) that can
translocate to the nucleus to activate the expression of its
target genes. There are four Notch receptor proteins36,
and western blot analysis demonstrates that CPX treat-
ment to T24 and UM-UC-3 cells enhanced the expression
of Notch 1, suppressed the expression of Notch 2 and
Notch 3, with no effect on Notch 4 expression (Fig. 5B).
Next, we evaluated the effect of CPX on γ-secretase
complex proteins in T24 and UM-UC-3 cells. CPX
treatment inhibited the expression of Presenilin 1,
Nicastrin, APH-1, and PEN-2 in both cell lines (Fig. 5C).
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Fig. 3 CPX induces apoptosis in bladder cancer cell lines. A T24 and UM-UC-3 cells were treated with CPX stained with Annexin V (FITC) and PI, and
analyzed by flow cytometry. CPX treatment induced significant early and late apoptosis in T24 and UM-UC-3 cells. B The flow cytometric quantification of
early and late apoptotic cells after CPX treatment over a period of 72 h in T24 and UM-UC-3 cells in Annexin-PI assay. C CPX induces apoptosis in T24 cells.
T24 cells treated with CPX (4 µM) for 48 h were stained with Annexin V-FITC/PI solution and studied using immunofluorescence. CPX induced apoptosis in
T24 cells. D Lysates from T24 and UM-UC-3 cells treated with CPX were studied by western blot for evaluating the effect on proteins involved in apoptosis.
CPX treatment reduced the levels of antiapoptotic marker proteins Bcl2 and Bcl-XL. CPX treatment also increases the PARP cleavage compared to untreated
controls. E CPX induces autophagy early which then followed by apoptosis. Lysates from T24 and UM-UC-3 cell treated with CPX (4 µM) for 24–48 h were
analyzed by western blot. CPX treatment increased the expression of LC3B at 24 h and cleaved caspase-3 expression at 48 h. The data suggest that at early
time points, CPX induces autophagy, which switches to apoptosis in T24 and UM-UC-3 cells.
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Fig. 4 CPX inhibits bladder cancer spheroid growth and cell migration. A, B CPX inhibits spheroid growth. CPX suppressed the size (A) and
number (B) of spheroids of bladder cancer cell lines. Cells were grown in spheroid growth media in ultralow adherent plates and treated with CPX 2 µM
and 4 µM concentrations for 5 days. CPX significantly decreased bladdosphere formation in the T24, UM-UC-3, HT-1376, HTB-9, and RT-4 cell lines. C CPX
inhibits the expression of bladder cancer stem cell marker proteins. Lysates from T24 and UM-UC-3 cell lines after CPX treatment were subjected to western
blot analysis. CPX treatment inhibited the expression of SOX9 and CD44 in both cell lines. D CPX inhibits migration of T24 and UM-UC-3 cells. Both cell lines
were grown to 95–100% confluency and a scratch was made to study the cell movement over a period of 12 h. CPX treatment reduced cell migration.
E CPX inhibited the percent migration in both cell lines. F CPX inhibits migration of T24 and UM-UC-3 cells. CPX treatment significantly reduced the
migration of both cell lines through transwell cell culture inserts (Boyden’s chamber). G The percent migraition is represented in graphical format.
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Fig. 5 CPX targets the Notch signaling pathway, through inhibition of the γ-secretase complex. A CPX inhibits mRNA expression of genes
involved in Wnt, Hedgehog, and Notch cell signaling pathways. RNA extracted from T24 cells treated with and without CPX for 48 h was used to
generate cDNA. The samples were analyzed using a Human stem cell RT2 profiler PCR array to identify signaling pathways that important for stem
cell maintenance like Notch signaling and Wnt signaling. Expression of Hes5, Lfng, Myc, and Notch 1 mRNAs were significantly downregulated after
CPX treatment. B CPX affects the expression of Notch receptors. Western blot analysis demonstrates that CPX treatment increased the expression of
Notch 1 and suppressed the activation of Notch 2 and Notch 3, while CPX has little to no effect on Notch 4. C CPX suppresses γ-secretase pathway
proteins. Western blot analysis of CPX-treated T24 and UM-UC-3 cell lysates showed CPX treatment reduced levels of Nicastrin, Presenilin 1, APH-1,
and PEN-2. D CPX suppresses notch signaling pathway ligand and downstream proteins. CPX increased the expression of ligand Jagged 1 and
inhibited the expression of downstream targets Hes1, cMYC, and Cyclin D1 in T24 and UM-UC-3 cells.
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Moreover, exposure to 4 µM CPX increased the expres-
sion of ligand Jagged 1 while decreasing the expression of
downstream target proteins Hes1, cMyc, and Cyclin D1 in
both T24 and UM-UC-3 cell lines (Fig. 5D).
The CPX-POM maximum tolerated dose (MTD) is 470mg/kg
We determined the maximum tolerated IP once-daily
dose of CPX-POM to support dose selection for the first
in vivo bladder cancer preclinical proof of principle study.
We administered acute (single) IP doses of fosciclopirox
ranging from 470, 700, and 930 mg/kg to three cohorts of
mice. The acute IP MTD was defined as 470mg/kg for
CPX-POM. Subsequently, ¼ acute MTD (117.5 mg/kg), ½
acute MTD (235mg/kg), and acute MTD (470mg/kg)
doses of CPX-POM were then administered once-daily IP
for ten consecutive days to three cohorts of healthy mice.
No drug-related clinical observations were observed in
any treatment group, confirming 470mg/kg CPX-POM as
the subchronic MTD in mice (data not shown).
The completed fosciclopirox First-in-Human Dose
Escalation Phase 1 (NCT03348514) trial in advanced solid
tumor patients defined the MTD in humans as 900mg/m2
administered intravenously over 10min37. Based on the
safety, dose tolerance, pharmacokinetics and pharmaco-
dynamics of CPX-POM in advanced solid tumor patients,
the MTD of 900mg/m2 infused intravenously over 20 min
was selected as the Recommended Phase 2 Dose (RP2D).
The ongoing fosciclopirox Phase 1 expansion cohort
study in muscle-invasive bladder cancer patients sched-
uled for cystectomy (NCT04608045) as well as ongoing
Phase 2 trial in newly diagnosed and recurrent urothelial
cancer patients scheduled for transurethral resection of
bladder tumors (NCT04525131) are evaluating the RP2D.
The human MTD (and RP2D) is quite comparable to the
subchronic MTD established in mice of 470mg/kg (which
is equivalent, based on body surface area, to 1343mg/m2
in the mouse).
CPX-POM selectively delivers CPX to the entire urinary
tract
The rate and extent of metabolism of CPX-POM was
determined in mice receiving CPX-POM and CPX-O at
10mg/kg IV. As illustrated in Fig. 6A, systemic CPX
exposure as measured by area under the plasma CPX
concentration-time curve, was similar following admin-
istration of the olamine salt of CPX compared to CPX-
POM demonstrating complete metabolism of CPX-POM
to CPX (data not shown). Complete metabolism of CPX-
POM to CPX was also observed in rats and dogs27. Given
this study demonstrated pharmacokinetic proof of prin-
ciple, we then determined the absolute bioavailability of
CPX-POM following IP administration (compared to the
IV route of administration) to support in vivo preclinical
proof of principle studies in the validated BBN mouse
model of bladder cancer. The rate of absorption of CPX
following IP administration of CPX-POM was rapid with
maximal plasma CPX concentrations observed at 15 min
post-dose (Fig. 6B). Mean (±SD) plasma CPX concentra-
tions declined rapidly at a similar rate following both
routes of administration. CPX-POM was not detectable in
plasma in any blood (plasma) sample collected following
IV or IP administration, demonstrating rapid and com-
plete metabolism of the prodrug to its active metabolite.
Plasma CPX pharmacokinetic parameters derived from
the resultant plasma CPX concentration-time data are
summarized in Supplementary Table 1. The absolute
bioavailability of IP CPX-POM in mice was 60% as mea-
sured by systemic exposure to the active metabolite. Sig-
nificant (10 µM) systemic CPX exposure was achieved
following IP administration of 117.5 mg/kg CPX-POM (¼
MTD) with a mean Cmax value of 4127 ng/mL. The
apparent elimination half-life of CPX following both
routes of administration was ~1 h. Systemic clearance of
CPX was 7353mL/h/kg. The extent of CPX distribution
was moderate with a steady-state volume of distribution
of ~5 L/kg.
In addition to characterizing systemic CPX exposure
following IP administration of CPX-POM, urinary
excretion of the active metabolite was characterized to
describe exposure to the urothelium in mice. Single-dose
and steady-state urinary excretion of CPX-POM, CPX,
and CPX-G was characterized in mice following once-
daily IP doses of 117.5 (¼ MTD), 235 (½ MTD), and
470mg/kg (MTD) CPX-POM for ten consecutive days
(Supplementary Fig. 4). Consistent with prior pharmaco-
kinetic studies conducted in mice, CPX-POM was not
detected in urine over the dose range studied, further
demonstrating complete metabolism of the prodrug to the
active metabolite. Despite the relatively short apparent
elimination half-life of CPX, mean urine CPX con-
centrations following single and repeated IP CPX-POM
doses were maintained over 24 h at concentrations well
above the in vitro IC50 value of 4 µM. This study
demonstrated that IP administration of CPX-POM at
well-tolerated doses in mice, in addition to achieving
adequate systemic exposure of CPX, delivers significant
concentrations of the active metabolite topically to the
urothelium. As a result, CPX-POM was evaluated in
in vivo preclinical proof of principle studies.
CPX-POM suppresses bladder tumorigenesis in vivo
To determine the effect of CPX-POM on bladder
tumorigenesis, we used a chemical carcinogen-induced
model that reproducibly establishes carcinoma in situ, and
if not treated, progresses to MIBC38. Mice were given
0.05% BBN in drinking water ad libitum for 16 weeks (Fig.
6C). Subsequently, CPX-POM was administered at 235 (½
MTD) and 470 (MTD) mg/kg IP once daily for 4 weeks.
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Vehicle control-treated mice exposed to the chemical
carcinogen demonstrated larger bladder weights than
control animals not exposed to BBN. Bladder weights, a
surrogate for tumor volume, in CPX-POM treated
animals exposed to BBN were significantly (p < 0.05) less
compared to vehicle control-treated mice exposed to the
chemical carcinogen (Fig. 6D). Pathologic analysis
revealed a distinct stage migration to lower stage tumors
Fig. 6 (See legend on next page.)
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in the two CPX-POM-treated groups compared to vehicle
control-treated mice (Supplementary Fig. 5). There was a
moderate to a strong correlation between treatment and
tumor stage (r2= 0.71, p= 0.12). IHC for Ki67, as a
marker of proliferation, showed high levels of positive
staining in bladder tumor tissues obtained from mice
exposed to just BBN. Following treatment with CPX-
POM, however, there was a reduction in Ki67 staining and
an increase in cleaved caspase-3 staining (Fig. 6E). Fur-
thermore, IHC analysis of bladder tumor tissues demon-
strated decreased staining for Notch 1, Presenilin 1, Hes1
and Nicastrin (Fig. 6E) in mice treated with CPX-POM. In
control mice, who were not exposed to BBN but were
treated with ½ MTD and MTD CPX-POM, there was no
evidence of toxicity to the urinary tract based on histo-
pathologic evaluation of kidneys, bladder, and ureters
(data not shown).
CPX targets γ-secretase proteins Presenilin 1 and Nicastrin
The data suggest that CPX downregulates the Notch
pathway in bladder cancer cells by inhibiting the γ-
secretase complex proteins Presenilin 1 and Nicastrin
(Fig. 7A). We profiled the expression of Presenilin 1 and
Nicastrin in 19 cancers within the Cancer Genome Atlas
(TCGA) database using TIMER2.0 online web server,
demonstrating that both genes had significantly higher
expression in the several cancer types examined (Fig. 7B).
Moreover, both the genes were upregulated in bladder
cancer tissues compared with normal bladder tissue
(Supplementary Fig. 6). Moreover, Kaplan–Meier survival
analysis showed that higher levels of Presenilin 1 and
Nicastrin expression (p < 0.05) were associated with sig-
nificantly poorer overall survival in patients with bladder
cancer (Fig. 7C). We next explored molecular docking
using the Autodock Vina software program to gain
insights into mechanisms of the inhibitory effects of CPX
on the two proteins. The docking data predicted that CPX
binds both Presenilin 1 and Nicastrin with the binding
energy of −5.4 and −6.4 Kcal/mol, respectively (Fig. 7D).
CPX stabilized itself by forming hydrogen bonds with
Asp385 (3.5 Å) and Asp436 (2.6 Å) of Presenilin 1 and
Nicastrin, respectively. The lower binding energy and
hydrogen bonding of CPX to these proteins suggested the
strong binding and a probable mechanism of inhibition of
the γ-secretase complex. Moreover, CPX interacted with
ASP385 residue of Presenilin 1, a residue that is essential
for the catalytic activity of the protein. This region has
been one of interest for designing γ-secretase complex
inhibitors for the treatment of Alzheimer’s Disease and
cancers39. Next, we used a cellular thermal shift assay
(CETSA) to confirm the binding to the two proteins. T24
cell lysates were treated with vehicle or CPX for 4 h fol-
lowed by denaturation using a thermal gradient. Thermal
denaturation of Presenilin 1 and Nicastrin starts at 66 °C
in vehicle-treated cells, while CPX treatment of T24 cells
provided protection to thermal denaturation up to 68 °C
and 70 °C for Presenilin 1 (Δ= 2 °C) and Nicastrin (Δ=
4 °C), respectively, (Fig. 7E, F). These data demonstrate
that CPX inhibits Notch activation by binding directly to
Presenilin 1 and Nicastrin.
Discussion
NMIBC remains a significant problem with high rates of
recurrence and progression to MIBC despite current
standard-of-care therapy. Likewise, current treatments for
MIBC and advanced disease rely on cisplatin-based che-
motherapy. Approximately 50% of MIBC patients are
either ineligible for cisplatin due to comorbidities, become
resistant during treatment, or decline chemotherapy prior
to cystectomy40. Although immunotherapy agents pem-
brolizumab and atezolizumab have been approved for the
treatment of platinum-ineligible metastatic urothelial
cancer patients whose tumors express high levels of PD-
L1, response rates have only been around 25%41. Further,
based on interim results from KEYNOTE-361 and
IMVIGOR-130 trials demonstrating decreased survival,
the FDA has warned against the use of these agents in
untreated patients with low PD-L1 expressing tumors42.
Thus, there is much room for improved outcomes in both
NMIBC and MIBC.
(see figure on previous page)
Fig. 6 CPX-POM treatment suppresses bladder tumorigenesis in vivo in the validated BBN mouse model of bladder cancer. A Mean (±SD)
plasma ciclopirox (CPX) concentration-time profiles following IV administration of 13.4 mg/kg CPX-POM and 18.1 mg/kg CPX-O to three C57BL/6
mice per serial blood collection time point per treatment group demonstrating rapid and complete metabolism of CPX-POM to its active metabolite,
CPX. B Mean (±SD) plasma CPX concentration-time profiles following administration of 23.4 mg/kg IV and 117.5 mg/kg IP CPX-POM to three C57BL/6
mice per serial blood collection time point per treatment group demonstrating acceptable bioavailability of CPX following IP administration of CPX-
POM. C Male C57BL/6 mice received 0.05% of N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) in the drinking water for 16 weeks. Mice were treated
with vehicle, 235 mg/kg CPX-POM (½MTD), or 470 mg/kg (MTD) CPX-POM IP once daily for 4 weeks (weeks 17–20). After 20 weeks, mice were
euthanized, bladder was collected weighed, and subjected to further analysis. D CPX-POM treatment significantly reduced the bladder weight as
compared to the vehicle-treated cohort at well-tolerated doses (p < 0.05). There were no statistically significant differences in bladder weights
between the 235mg/kg (½ MTD) and 470mg/kg (MTD) CPX-POM treatment cohorts. E Immunohistochemistry analysis of bladder tumors obtained
from CPX-POM-treated mice show a lower number of PCNA-positive nuclei compared to bladder tumors obtained from vehicle-treated mice.
Bladder tumors obtained from CPX-POM treated mice also showed reduced expression of Notch 1, Presenilin 1, Hes1, and Nicastrin and increased
levels of cleaved caspase-3 compared bladder tumors obtained from vehicle-treated mice.
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Fig. 7 CPX targets γ-secretase complex proteins Presenilin 1 and Nicastrin. A Schematic representation showing the Notch signaling pathway. CPX
targets γ-secretase target proteins Presenilin 1 and Nicastrin in bladder cancer cells. B mRNA expression of Presenilin 1 and Nicastrin in different cancer
patients in the Cancer Genome Atlas database, extracted from Timer 2.0. (Bladder Urothelial Carcinoma [BLCA], Breast invasive carcinoma [BRCA], Cervical
squamous cell carcinoma and endocervical adenocarcinoma [CESC], Colon Adenocarcinoma [COAD], Esophageal Squamous Cell Carcinoma [ESCA],
Glioblastoma multiforme [GBM], Head and Neck squamous cell carcinoma [HNSC], Kidney renal clear cell carcinoma [KIRC], Liver hepatocellular carcinoma
[LIHC], Lung adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC], Pancreatic adenocarcinoma [PAAD], Prostate adenocarcinoma [PRAD], Rectum
adenocarcinoma [READ], Stomach adenocarcinoma [STAD], Thyroid carcinoma [THEA], Uterine Corpus Endometrial Carcinoma [UCEC]). C Kaplan–Meier
survival analysis showed that higher levels of Presenilin 1 or Nicastrin expression (p< 0.05) were significantly associated with poor overall survival in patients
with bladder cancer. D The molecular docking analysis predicted the binding of CPX in the protein cavity of Presenilin 1 and Nicastrin. AutoDock Vina
software program was used for molecular docking. E Cellular thermal shift assay (CETSA). T24 cell lysates were treated with CPX and subjected to differential
temperature treatment for 3mins and evaluated using western blot analyses. CPX protected Presenilin 1 and Nicastrin against thermal degradation,
suggesting the active metabolite of CPX-POM interacts with these proteins. F Cumulative results from the densitometric evaluation of CETSA assay.
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Our studies demonstrate that in vitro exposure to the
active metabolite of CPX-POM, ciclopirox, resulted in a
significant dose- and time-dependent decrease in cell
proliferation and colony formation of high-grade human
urothelial cancer cell lines. Furthermore, CPX exposure
significantly decreased spheroid formation and cancer
stem cell marker proteins (CD44 and SOX9), suggesting
that CPX acts, at least in part, through effects on CSCs.
Further studies are ongoing to understand mechanisms by
which CPX directly affects stemness, including deter-
mining the effect of the active metabolite on stem cell
marker expression. Nevertheless, we have observed that
CPX affects Notch signaling by targeting γ-secretase
complex proteins Presenilin 1 and Nicastrin. Initial stu-
dies suggested a tumor-suppressor role for the Notch
signaling pathway43,44. However, additional studies sug-
gested that while the tumor-suppressor role may reside
with Notch 1, Notch 2 acts more like an oncogene, and
therefore, targeting Notch 2 may have merit35,45. Fur-
thermore, Notch 3 was shown to be overexpressed in
bladder cancer and is associated with poorer treatment
outcomes46. Moreover, Notch 1 levels were found to be
high in a population of cells marked by the putative stem
cell marker ABCB247. This suggests that while Notch 1
may not play a role in proliferation of bladder cancer cells,
it has a key player in CSCs, resulting in aggressive tumor
growth. Further studies are required to delineate the role
of Notch proteins in cancer stemness, proliferation,
migration, and invasion.
CPX exposure also significantly increased the per-
centage of cells arrested at S-phase and G0/G1, con-
sistent with its ability to decrease cyclin D1. Initial
studies have also suggested that CPX acts as a G1/S-
phase transition blocker of a promyelocytic leukemia
cell line HL6022. However, Ewing sarcoma cells treated
with CPX were found to accumulate in the S-phase13.
Moreover, this was observed as a result of inhibiting
ribonucleotide reductase M2, the iron-dependent sub-
unit of ribonucleotide reductase11. Initially, when CPX
was found to inhibit urothelial cancer cell growth, we
also explored if this was due to iron chelation. Defer-
oxamine, an iron chelator, did not affect urothelial
cancer cell viability suggesting that the effects observed
following CPX exposure are not due to suppressing
ribonucleotide reductase activity33. On the other hand,
we have observed that CPX binds γ-secretase complex
proteins Presenilin 1 and Nicastrin to inhibit Notch
signaling, suggesting that CPX targets the γ-secretase
complex in bladder cancer cells. However, Notch
receptors may not be the only substrate and that there
may be additional targets. In this regard, proteomic
profiling of HeLa cells for γ-secretase substrates iden-
tified multiple targets including the human leukocyte
antigen, the low-density lipoprotein receptor and
syndecan−1 and −238. Nevertheless, these studies
suggest that the effect of CPX may be dependent on the
cell line.
Ciclopirox, as the free acid or olamine salt, lacks the
water solubility necessary to formulate the drug as a
parenteral drug product. In contrast, fosciclopirox (CPX-
POM) possesses outstanding aqueous solubility and is
easily formulated into an injectable solution. In vitro
studies demonstrated that CPX-POM and CPX-G have
little (IC50 > 50 µM) to no anticancer activity. Fosciclo-
pirox is rapidly and completely metabolized to the active
metabolite, CPX, via circulating, high capacity phospha-
tases48. As such, fosciclopirox meets the definition of a
prodrug. IP administration of well-tolerated CPX-POM
doses results in selective delivery of CPX to the entire
urinary tract, not only achieving urine concentrations but
also exceeding in vitro IC50 values by several fold. Urinary
tract exposure to CPX at well-tolerated doses is associated
with in vivo responses in the BBN model.
In contrast to standard-of-care NMIBC treatments
administered to patients by bladder instillation (this route
of delivery does not deliver drug to the upper urinary
tract), systemic administration of CPX-POM delivers its
active metabolite, CPX to the entire urinary tract, which is
critical given the often-multifocal nature of urothelial
carcinoma and its propensity for recurrence. To deter-
mine whether systemic and urinary tract drug exposure
was sufficient to achieve in vivo antitumor response, we
employed the BBN mouse model of bladder cancer rather
than a xenograft model. As described above, this model
reproducibly creates high-grade, basal-type tumors
exclusively within the urinary tract without toxicity else-
where in the body49. Without intervention, high-grade
tumors progress to muscle-invasive disease. Based on our
experiences evaluating several agents with different pro-
posed mechanisms of action in the BBN model, we pre-
defined criteria for drug response as ≥30% difference in
bladder weights and ≥25% migration to lower stage
tumors. We demonstrated a clear and selective effect on
tumor development and tumor downstaging as a result of
treatment with CPX-POM. In addition, we demonstrated
inhibition of cell proliferation in bladder tumor tissues.
There were also dose-dependent reductions in Notch 1,
Presenilin 1, and Hes 1 in tissues from the BBN groups
treated with CPX-POM supporting the hypothesis that
CPX-POM acts, at least in part, by inhibiting Notch sig-
naling. This BBN study demonstrated antitumor response
at subchronic once-daily IP doses of 235 (½MTD) and 470
(MTD) mg/kg, thus, providing the rationale for advancing
fosciclopirox to early phase clinical trials.
The safety, dose tolerance, pharmacokinetics and
pharmacodynamics of CPX-POM has been characterized
in 19 advanced solid tumor patients participating in the
US multisite first-in-human Phase 1 trial (NCT03348514).
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Based on the safety, dose tolerance, pharmacokinetics,
and pharmacodynamics of CPX-POM in advanced solid
tumor patients, the MTD of 900 mg/m2 infused intrave-
nously over 20min was selected as the Recommended
Phase 2 Dose (RP2D)37. A Phase 1 expansion cohort study
is ongoing at three US sites, evaluating CPX-POM in
cisplatin-ineligible and chemotherapy eligible muscle-
invasive bladder cancer patients scheduled for cystect-
omy (NCT04608045). A Phase 2 trial in newly diagnosed
and recurrent urothelial cancer patients scheduled for
transurethral resection of bladder tumors is also ongoing
at one US site (NCT04525131). The Phase 1 expansion
cohort and Phase 2 CPX-POM trials are designed to
establish clinical proof of concept, including demonstra-
tion of Notch signaling modulation in bladder tumors
through γ-secretase complex inhibition. The fosciclopirox
RP2D currently being studied in ongoing Phase 1 and
Phase 2 clinical trials is quite comparable to the CPX-
POM doses of 235mg/kg (671.5 mg/m2) and 470 mg/kg




CPX-POM is rapidly and completely metabolized in
blood to its active metabolite, CPX, in mice, rats, and dogs
via circulating phosphatases27. Given cell culture media
lack phosphatases required to form CPX, ciclopirox ola-
mine (CPX-O, Sigma–Aldrich, CAS Number 41621-49-2,
molecular formula C12H17NO2, molecular weight 268.35)
was purchased and used in the majority of in vitro studies
(with the exception of in vitro studies conducted estab-
lishing that CPX-POM and the glucuronide metabolite of
CPX possess minimal to no antiproliferative activity in
urothelial cancer cells). Similarly, ciclopirox ß-D-glucur-
onide (CPX-G, Santa Cruz Chemical, CAS Number
79419-54-8, molecular formula C18H25NO8, molecular
weight 393.39) was purchased to characterize in vitro
activity of this metabolite. Ciclopirox Prodrug, disodium
((6-cyclohexyl-4-methyl-2-oxopyridin-1(2H)-yl)oxy)
methyl phosphate heptahydrate (CPOX-POM, Fig. 1A),
has a molecular formula of C13H32NNa2O13P and mole-
cular weight of 487.35 g/mol. CPX-POM has been given
the provisional International Nonproprietary Name (INN)
of fosciclopirox. CPX-POM exists as a white solid, has
excellent water solubility, and possesses solution stability
for parenteral administration. For in vivo preclinical stu-
dies described herein, CPX-POM was supplied as a non-
preserved, sterile solution for IV and IP injection at a
concentration of 50 mg/mL. The formulation included the
active ingredient, CPX-POM disodium heptahydrate,
sterile water for injection as a solvent, dibasic sodium
phosphate (anhydrous) as a buffer, and sodium hydroxide
and hydrochloric acid for pH adjustment.
The cancer genome atlas (TCGA)
The gene expression and survival data of TCGA were
analyzed by using the TIMER2.0 (http://timer.
cistrome.org)50,51 and Human Protein Atlas (https://
www.proteinatlas.org/).
Cell lines
T24, UM-UC-3, HTB-5, HTB-9, RT-4, and HT-1376
cell lines were purchased from ATCC and used for this
study. All cell lines were maintained as per ATCC’s media
recommendations with 10% FBS and 1% penicillin/
streptomycin. All experiments were performed before 10
passages.
Cell proliferation assays
To determine the effect of CPX, the active metabolite of
CPX-POM, on bladder cancer cell proliferation, T24,
UM-UC-3, HTB-5, HTB-9, RT-4, and HT-1376 cells were
exposed to several CPX exposure conditions during which
concentration and exposure duration were varied. Five
thousands cells per well were seeded on 96-well plates and
grown overnight. Cells were then treated with decreasing
concentrations of CPX (a range of 0–40 μM) in a Dul-
becco’s modified Eagle’s Medium containing 10% fetal
bovine serum. Cell proliferation by the hexosaminidase
assay52 was measured at 24, 48, and 72 h following
removal of CPX from cell culture. Briefly, the medium was
removed and hexosaminidase substrate solution in citrate
buffer pH 5 (7.5 mM), p-nitrophenol-N-acetyl-beta-D-
glucosaminidase (Sigma–Aldrich) was added at 85 µL per
well. The plate was incubated at 37 °C in 100% humidity
for 30min. The reaction was stopped with addition of
112.5 μL of 50mM glycine containing 5mM of ethyle-
nediaminetetraacetic acid (pH 10.4). Absorbance was
measured at 405 nm. We used four wells for each group
and the experiment was repeated three times. Data were
analyzed as a percent of control, where control wells were
treated with equivalent amounts of dimethyl sulfoxide
alone. For IC50 calculations, a plot between the drug
concentration and hexosaminidase activity was generated
and the data were fitted either linearly or exponentially.
The best fit was used for further processing of data. IC50
for each human urothelial cancer cell line was determined
as the CPX concentration resulting in 50% of maximal cell
death observed after 48 h of continuous exposure.
Colony formation assay
The effect of CPX on colony formation was assessed
using the clonogenicity assay, in which six-well plates
were seeded with 500 viable bladder cancer cells (T24,
UM-UC-3, HTB-5, HTB-9, RT-4, and HT-1376) and
grown overnight. The cells were then incubated in the
presence or absence of various concentrations (0–20 µM)
of CPX for 48 h. The CPX-containing medium was
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removed, and cells were washed in phosphate-buffered
saline (PBS) and incubated for an additional 10 days in a
drug-free medium; and the experiment was repeated three
times. The colonies obtained were washed with PBS and
fixed in 10% formalin for 10min at room temperature
then washed with PBS followed by staining with 1%
crystal violet solution. The cell colonies formed were
compared to those observed in untreated cells.
Spheroid formation assay
Using the spheroid assay (bladdosphere assay) to
examine the spheroid formation, bladder cancer cells
were plated in ultralow binding plates. For the formation
of spheroids, cells were cultured in DMEM supplemented
with 20 ng/mL fibroblast growth factor-basic (Invitrogen),
10 mL per 500mL of 50× B27 supplement (Invitrogen),
epidermal growth factor 20 ng/mL (Invitrogen), and
antibiotic and antimycotic solution. Cells were seeded at
low densities (200–1000 cells/mL) in 96-well low-adhe-
sion plates. Cells were treated with CPX at 1/2 IC50, and
IC50 values generated using the cell proliferation assay
described above. After 7 days of CPX incubation at these
concentrations, control and bladder cancer spheroids
were photographed. Four wells per group were used and
the experiment was repeated three times.
Scratch plate assay
Migration of bladder cancer cells was measured using
an “in vitro wound-healing assay” (or scratch plate assay)
performed in a six-well plate (Becton Dickinson). Briefly,
T24 and UM-UC-3 cells were seeded and grown to near
confluent monolayers in 10% FBS-supplemented culture
medium. Using a sterile 10 μL pipette tip, perpendicular
wounds were scratched through the cell monolayer fol-
lowed by PBS washing two times. The scratched areas
were photographed at ×10 magnification using computer-
assisted microscopy. Cells were treated with vehicle and
CPX at ½ IC50 and IC50 determined for this urothelial
cancer cell line, and the experiment was repeated three
times. After 12 h of incubation in a humidified incubator
at 37 °C with 5% CO2, and each well was photographed at
10X magnification and analyzed for wound closure.
Migration and invasion assay
Bladder cancer cell (T24 and UM-UC-3) migration and
invasion were studied in a Boyden chamber consisting of a
cell culture insert (8-μm pore polyethylene terephthalate
membrane), seated in each well of a 24-well companion
plate. T24 and UM-UC-3 cells were seeded in the upper
chamber of an insert in serum-free media and positioned
in a 24-well plate containing serum-containing media.
The cells were treated with CPX at ½ IC50 and IC50. The
migration is carried out in a humidified incubator at 37 °C
with 5% CO2 for 12 h. After 12 h, inserts were removed,
washed with PBS three times, and cleaned with cotton
swabs to remove nonmigratory cells. The cells were fixed
with 10% formalin, stained with DAPI and photographed
and counted. For invasion assay, matrigel was thawed on
ice and diluted in serum-free DMEM in a 1:1 ratio. 50 µL
of Matrigel is added to a 24-well transwell insert and kept
in a 37 °C incubator for 15–30min to form a thin gel
layer. T24 cells were plated on top of Matrigel in serum-
free media and treated with CPX. Invasion was carried out
in a humidified incubator at 37 °C with 5% CO2 for 12 h.
Nonmigratory cells on the upper side of the insert con-
taining Matrigel were removed with a cotton swab. Then,
cells on matrigel were fixed with formalin and stained
with Hoechst dye. For quantification, randomly selected
fields on the lower side of each insert were photographed.
Flow cytometry for cell cycle determination
Flow cytometry-based cell cycle analysis studies were
conducted to determine the effect of CPX on cell cycle
progression in T24 and UM-UC-3 bladder cancer cells.
Cells were treated with 4 µM CPX, for 24 and 48 h. T24
and UM-UC-3 cells were then trypsinized and suspended
in PBS. Single-cell suspensions were fixed using 70%
ethanol for 2 h and subsequently permeabilized with PBS
containing 1 mg/mL propidium iodide (Sigma–Aldrich),
0.1% Triton X-100 (Sigma–Aldrich), and 2 mg DNase-
free RNase (Sigma–Aldrich) at room temperature. Flow
cytometry was performed with a FACSCalibur analyzer
(Becton Dickinson, Mountain, View, CA, USA), captur-
ing 50,000 events for each sample. Results were analyzed
with ModFit LT software (Verity Software House,
Topsham, ME).
Apoptosis assay
Immuno-fluorescent based studies were conducted to
determine the effect of CPX on apoptosis in T24 and UM-
UC-3 bladder cancer cells. Cells were seeded in six-well
plates at 1 × 105 cells/well and treated with 4 μM (IC50) CPX
at 37 °C for 72 h. Next, T24 and UM-UC-3 cells were
trypsinized and collected for the detection of apoptosis using
Annexin V-FITC Apoptosis Detection Kit (eBioscience, San
Diego, CA, USA). Briefly, T24 and UM-UC-3 cells were
washed twice with cold PBS and resuspended in 500 µL
binding buffer (10mM HEPES-NaOH pH 7.4, 140mM
NaCl, 2.5mM CaCl2) at a concentration of 1 × 106 cells/ml.
After the addition of 5 μl Annexin V-FITC solution and PI
(1 μg/ml), the cells were incubated for 15min at room
temperature and then analyzed by Flow cytometry and
Nikon Eclipse Ti microscope (Nikon Inc., Melville, NY).
Quantitative PCR for cancer stem cell signaling pathway
expression
Gene expression analysis was performed on T24 cells
exposed to 4 µM CPX for up to 48 h using RT2 Profiler™
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polymerase chain reaction (PCR) Arrays (SA Biosciences,
Frederick, MD, USA) per the manufacturer’s instructions.
The human signal transduction pathway finder PCR array
was used (cat. no. PAHS-014ZA). Total RNA isolated
from T24 cells using TRIZOL reagent was reverse tran-
scribed with Superscript II reverse transcriptase in the
presence of random hexanucleotide primers (all from
Invitrogen, Carlsbad, CA). Complementary DNA (2 μg)
was mixed with 1275 μL RT2 SYBR Green qPCR Master
Mix (PA-010; SA Biosciences) to make up a total volume
of 2550 μL. Each well received 25 μL of this mix. Quan-
titative PCR was performed on a Bio-Rad CFX machine
following detection protocols recommended by SA Bios-
ciences. Cycle threshold values for a reaction set were
analyzed online at the manufacturer’s web site (http://
www.sabiosciences.com/pcr/arrayanalysis.php). Changes
in mRNA expression were expressed as fold change
relative to control.
Western blot analysis
Western blot analysis was used to determine the effect
of CPX exposure on protein expression of key compo-
nents of the Notch signaling pathway. T24 and UM-UC-3
cells were exposed to 4 μM CPX for 48 h, after which cells
were collected and lysed with cell lysis buffer. Cell lysates
collected following centrifugation were subjected to
polyacrylamide gel electrophoresis and blotted onto
Immobilon polyvinylidene difluoride membranes (Milli-
pore, Bedford, MA, USA). Antibodies specific for the four
Notch isoforms were purchased from Cell Signaling
Technology (Beverly, MA, USA), Abcam Inc. (Cambridge,
MA, USA) and Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA) and specific proteins were detected by
the enhanced chemiluminescence system (GE Healthcare,
Piscataway, NJ, USA). T24 and UM-UC-3 cells were
exposed to 4 μM CPX for 48 h, after which time cells were
collected and lysed with cell lysis buffer. Cell lysates col-
lected following centrifugation were subjected to poly-
acrylamide gel electrophoresis and blotted onto
Immobilon polyvinylidene difluoride (PVDF) membranes
(Millipore, Bedford, MA, USA). The PVDF membranes
were incubated overnight at 4 °C with primary antibodies
specific for cyclin D1 (Cat no. 2978), B1 (Cat no.4138), A2
(Cat no.4656) and E (Cat no.4129), BCL2 (Cat no.15071),
BCL-XL (Cat no. 2764), BAX (Cat no. 2772), PARP (Cat
no.9532), cleaved Caspase-3 (Cat no.9664), LC3B (Cat
no.2775), Notch 1–4 (Cat no.03608,5732, 5276, 2423),
Jagged 1 (Cat no. 2155), Presenilin 1 (Cat no.5643),
Nicastrin (Cat no.3632), APH-1 (Cat no. PA5-20317),
SOX2 (Cat no. 3579), CD44 (Cat no. 37259,) and PEN-2
(Cat no.8598) were purchased from Cell Signaling
Technology (Beverly, MA, USA) and used in 1:1000
dilution. GAPDH (Cat no. sc-365062) was purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA) and used in 1:2000 dilution. Next day, the
membranes were washed and incubated with respective
anti-mouse or anti-rabbit secondary antibody
(Sigma–Aldrich, Saint Louis MO, USA) for 1 h at room
temperature. The specific proteins were detected by the
enhanced chemiluminescence system (GE Healthcare,
Piscataway, NJ, USA). Western blots were visualized by
Bio-Rad ChemiDoc-XRS+ instrument and analyzed by
image lab software (Bio-Rad, CA, USA).
Molecular docking
The AutoDock Vina software program53 was employed
to study the interaction of CPX and γ-secretase complex
proteins Presenelin-1 (PDB ID: 2KR6) and Nicastrin (PDB
ID: 4R12)54. AutoDock Vina is freely available software
which has shown high performance and accuracy for
structural-based virtual screening of compounds. For
docking analysis, the 3D-grid was generated surrounding
the catalytic residue ASP385 in the case of Presenilin 1
and we used grid parameters as published by Pal et al.55
for Nicastrin. A grid center co-ordinate consisting of grid
spacing of 1.0 Å and 40X40X40 point size was utilized.
We used default parameters of the AutoDock Vina tools
for preparation of proteins and CPX. Total Kollman and
Gasteiger charges were added to proteins before per-
forming docking and the Lamarckian generic algorithm
was used to predict topmost conformations. About 10
conformations for each protein-CPX complex were stu-
died. The most favorable conformation was selected based
on the number of hydrogen bonds and the lowest binding
energy. The resulting complex was evaluated and visua-
lized using Pymol (https://pymol.org/2/)56.
Cellular thermal shift assay (CETSA)
The ability of CPX to interact with Presenilin 1 and
Nicastrin was evaluated by using CETSA57. Briefly, T24
cells were cultured and grown to 70–80% confluency.
Cells were lysed using lysis buffer and diluted to the
concentration of 3 mg/ml. The cell lysates were incubated
with vehicle or CPX (20 μM) for 4 h. Next, the cell lysate
was aliquoted into PCR tubes and subjected to heat gra-
dient (44–80 °C) for 3 min. Subsequently, cells were cen-
trifuged for 20min. The resultant proteins were diluted
with 4× Laemmli buffer, boiled at 95 °C for 5 min and
loaded onto 10% SDS-PAGE gel, transferred to PVDF
membrane and incubated overnight with Presenilin 1
(Cell Signaling # 5643) and Nicastrin (Cell Signaling #
3632) antibodies at a concentration of 1:1000. The wes-
tern blot was visualized by Bio-Rad ChemiDoc-XRS+
instrument and analyzed by image lab software.
Animals
Male C57BL/6 mice were selected for all in vivo pre-
clinical studies consistent with the validated N-butyl-N-
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(4-hydroxybutyl)-nitrosamine (BBN) chemical carcinogen
model of bladder cancer described below. The in-life
portions of the maximum tolerated dose and pharmaco-
kinetic studies were conducted at the AAALAC-
accredited animal facility at Xenometrics LLC, Stilwell,
KS. The BBN study was conducted at the University of
Connecticut Health Center in Farmington, CT. All animal
studies were approved by the Institutional Animal Care
and Use Committees at the two institutions.
Maximum tolerated dose study
The intraperitoneal (IP) acute and subchronic max-
imum tolerated doses (MTD) of CPX-POM were deter-
mined in fasted male C57BL/6 mice under study
conditions according to the principles of Good Laboratory
Practices (GLP). In the acute MTD phase, mice were
given a single IP dose of CPX-POM. Doses were given
under a flexible dosing regimen adopted from OECD
Acute Oral Toxicity Test Guideline 425, Up-and-Down
Acute Toxicity Procedure58. Doses were based on the
tolerability, as determined by clinical observations, of the
previous dose. Animals were observed for a minimum of
two hours post-dose. Subsequent doses were adjusted
based on observations of drug-related adverse effects (if
any) from the previous dose. Dosing was staggered with
five mice studied per dose group. Parameters examined
included mortality, morbidity, clinical observations, and
body weights. In dose cohort 1, IP doses were adminis-
tered at a volume of 20mL/kg resulting in a dose of
940mg/kg as CPX-POM; in dose cohort 2, IP doses were
administered at a volume of 10mL/kg resulting in a dose
of 470mg/kg as CPX-POM; in dose cohort 3, IP doses
were administered at a volume of 15 mL/kg resulting in a
dose of 705 mg/kg as CPX-POM. Based on clinical
observations from the first three treatment groups it was
determined that additional dose groups were unnecessary.
In the subchronic MTD phase, once-daily IP doses of
CPX-POM were administered for 10 consecutive days to
three treatment groups of ten mice each. Vehicle was
administered IP once daily to a control group of ten mice
as well. Dose levels for the subchronic MTD phase were
selected based on the determination of the acute MTD. IP
doses of test article were administered at volumes of
2.5 mL/kg, 5 mL/kg, and 10mL/kg, resulting in doses of
117.5 mg/kg, 235mg/kg, and 470 mg/kg, respectively, as
CPX-POM. Doses were administered volumetrically
based on the most recent body weight of the animal.
Consistent with the acute MTD phase of this study,
parameters examined included mortality/morbidity, clin-
ical observations, and body weights. In addition, necrop-
sies were performed on each animal with kidneys, liver,
urinary bladder, and urinary tract tissues collected. Based
on the absence of gross pathology findings, these tissues
were not further processed.
Pharmacokinetic studies
The pharmacokinetics of CPX-POM were characterized
following IV and IP administration to 72 fasted male
C57BL/6 mice. IP doses were administered at 117.5 mg/kg
to Treatment Group 1 (n= 30) and 2 (n= 6), and IV
doses at 23.5 mg/kg to Treatment Group 3 (n= 30) and 4
(n= 6). Serial blood (plasma) samples were collected via
cardiac puncture from Treatment Groups 1 and 3 at the
following time points: predose, 0.083, 0.167, 0.25, 0.5,
0.75, 1, 1.5, 2, 3, and 4 h post-dose. Metabolism Cages
were used to collect complete urine from Treatment
Groups 2 and 4 at the following urine collection intervals:
predose, 0–4, 4–8, and 8–24 h post-dose.
Once the subchronic MTD of IP CPX-POM was
defined, single-dose and steady-state urinary concentra-
tions of CPX were characterized in six mice per dose
cohort at MTD (470mg/kg), ½ MTD (235mg/kg), and ¼
MTD (117.5 mg/kg). Complete 24-h urine samples were
collected using metabolism cages with three mice housed
per cage per dose cohort. Urine samples were collected
prior to dosing as well as over 0–8 h and 8–24-h collec-
tion intervals starting on days 1 (single dose) and 10
(steady-state). Urine samples were collected frozen on dry
ice into glass collection jars, thawed, transfer into tared
plastic jars, and weighed. All urine was stored at −20 ±
5 °C until shipment to the bioanalytical laboratory for
analysis.
In vivo preclinical proof of principle in a mouse model of
bladder cancer
The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)
chemical carcinogen model was selected to determine
in vivo preclinical proof of principle. This is a well-known
and validated model for bladder cancer49. It reproducibly
creates carcinoma in situ at ~16 weeks of BBN exposure
via the drinking water at 0.05% concentration. The
tumors are genetically similar to the basal phenotype
described in humans and is a suitable model for pre-
clinical testing of novel agents49. Without intervention,
carcinoma in situ observed following 16 weeks of expo-
sure to BBN will progress from NMIBC to MIBC. Based
on our experiences evaluating several agents with differ-
ent proposed mechanisms of action in the BBN model, we
predefined criteria for drug response as ≥30% difference
in bladder weights and ≥25% migration to lower stage
tumors. Seventy-five male C57BL/6 mice were divided
into six treatment cohorts. Three cohorts of 19 animals
each were exposed to BBN for 16 weeks, after which time
mice were treated with either vehicle, 235mg/kg CPX-
POM, or 470 mg/kg CPX-POM IP once daily for 4 weeks
(weeks 17–20). Three control treatment cohorts (six mice
per group) received drinking water absent BBN. After
16 weeks, the three control cohorts were treated with
either vehicle, 235mg/kg CPX-POM, or 470mg/kg CPX-
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POM IP once daily for 4 weeks (weeks 17–20). The
vehicle contained 50mM Captisol in 25mM phosphate
buffer, pH 7.0. Animals were inspected daily for general
health, with weights recorded biweekly throughout the
study. At the end of the study, the animals were eutha-
nized. Bladders were harvested, weighed, then inflated
with and placed in 10% buffered formalin in phosphate-
buffered saline for 24 h then transferred to phosphate-
buffered saline. Formalin-fixed bladders were bisected and
embedded along the midsagittal plane and serially sec-
tioned for whole-mount pathologic analysis. Evaluation of
tissues was performed by a board-certified pathologist in a
blinded fashion. Hematoxylin- and eosin-stained slides
were assessed for tumor stage and grade. Immunohis-
tochemistry for cell proliferation proteins Ki67 (Cat. No.
AB9260, Sigma–Aldrich, St. Louis, MO, USA), apoptosis
protein cleaved caspase-3 (Cat. No. 9579, Cell Signaling
Technology, Beverly, MA, USA) were performed using
UltraVision™ Quanto Detection System (ThermoFisher,
Waltham, MA, USA). Immunohistochemistry for Notch
signaling proteins was also performed, specifically the
expression of Notch 1 (Cat. No.3608), Hes1 (Cat. No.
11988, Cell Signaling Technology, Beverly, MA, USA),
Presenilin 1 (Cat.No. MA1-752), and Nicastrin (Cat. No.
PA5-20304, ThermoFisher, Waltham, MA, USA).
Bioanalysis
Mouse plasma and urine bioanalytical methods were
developed and validated under the principles of GLP for
three analytes including CPX-POM, the active metabolite
CPX, and the inactive metabolite ciclopirox glucuronide
(CPX-G). Methods employed liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to quantitate
plasma and urine concentrations of CPX-POM metabo-
lites. The upper (ULOQ) and lower limits of quantitation
(LLOQ) for CPX-POM in plasma and urine were 100 and
5000 ng/mL, respectively. The ULOQ and LLOQ for CPX
in both plasma and urine were 25 and 5000 ng/mL,
respectively. The urine CPX-G method had ULOQ and
LLOQ limits of 250 ng/mL and 5000 ng/mL.
Pharmacokinetic data analysis
Nonparametric pharmacokinetic parameters were gen-
erated from resultant plasma and urine drug/metabolite
concentration-time data using Phoenix WinNonlin (Cer-
tara™ Version 6.3) software. Nominal blood sampling
times were used given blood (plasma) and urine samples
were collected without exception per sampling times
defined in study protocols. Predose plasma drug/meta-
bolite concentrations reported as less than LLOQ were
designated as below the quantifiable limit (BQL) and
treated as zero in the calculation. BQL values observed in
the terminal phase of the plasma drug/metabolite
concentration-time profile were treated as missing in
determination of the apparent first-order elimination rate
constant and area under the plasma drug/metabolite
concentration-time curve. Given the absence of quantifi-
able concentrations of CPX-POM in plasma and urine,
pharmacokinetic data analysis was not performed for
parent drug. Descriptive statistics (mean ± standard
deviation) were calculated for the resultant plasma and
urine CPX and CPX-G pharmacokinetic parameters.
Inferential statistical analyses were not performed given
the objectives of the two pharmacokinetic studies.
Statistical analysis
All values are expressed as the mean ± SD. Data were
analyzed using an unpaired two-tailed t-test. A p-value of
less than 0.05 was considered statistically significant.
Inferential statistical analyses were performed using SPSS
software (IBM Corp., Somers, NY). In addition, a one-way
analysis of variance (ANOVA) was performed for multiple
comparisons. Post-hoc testing was performed with two-
sided Dunnett’s tests. The number of tumors and tumor
stage were compared across treatment groups using
cross-tabulation and correlation with treatment evaluated
with the Pearson Chi-Square test. P-values are repre-
sented as *p < 0.05, **p < 0.01, ***p < 0.001.
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